Eleven years of HPV vaccine surveillance affirms safety

24 August 2020

A new large-scale study analysing surveillance data over 11 years has affirmed the safety of quadrivalent human papillomavirus (4vHPV) vaccine among both boys and girls. 

The study led by authors from NCIRS and the University of Sydney examined all adverse events following immunisation with 4vHPV vaccine reported to the Therapeutic Goods Administration (TGA) from 2007 to 2017.

The analysis did not reveal any new or concerning safety issues

Read more here

Keep up to date with Immunisation information on our PHN Immunisation webpage

Keep up to date with coronavirus information on our PHN Coronavirus webpage.